Breaking News
Get 40% Off 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

Athersys Inc (ATHXQ)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.0045 +0.0012    +36.36%
20/04 - Closed. Currency in USD ( Disclaimer )
After Hours
0.0045
0.0000
0.0000%
5:52:43 - Delayed Data
  • Volume: 899,475
  • Bid/Ask: 0.0000 / 0.0000
  • Day's Range: 0.0018 - 0.0060
Type:  Equity
Market:  United States
Athersys 0.0045 +0.0012 +36.36%

Athersys Inc Company Profile

 
Get an in-depth profile of Athersys Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

24

Equity Type

ORD

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company’s lead platform product includes MultiStem cell therapy, an allogeneic stem cell product for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. The company was founded in 1995 and is headquartered in Cleveland, Ohio. On January 5, 2024, Athersys, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Northern District of Ohio.

Contact Information

Address 3201 Carnegie Avenue
Cleveland, 44115-2634
United States
Phone 216 431 9900
Fax 216 361 9495

Top Executives

Name Age Since Title
James G. Shook 84 2000 Scientific and Clinical Advisor
Michael Simons - - Scientific and Clinical Advisor
Warren Sherman 73 - Scientific and Clinical Advisor
Marc Steven Penn - - Scientific and Clinical Advisor
Ira Mellman - - Scientific and Clinical Advisor
Robert F. Kushner - - Scientific and Clinical Advisor
Jerry Silver - - Scientific and Clinical Advisor
Gilbert Clincke - - Scientific and Clinical Advisor
Brian H. Annex - - Scientific and Clinical Advisor
F. Xavier Pi-Sunyer - - Scientific and Clinical Advisor
Larry Wechsler - - Scientific and Clinical Advisor
John Wagner - - Scientific & Clinical Advisor
Richard T. Maziarz - - Scientific & Clinical Advisor
Hillard M. Lazarus - - Scientific & Clinical Advisor
C. Thomas Caskey 84 2000 Scientific and Clinical Advisor
Catherine Verfaillie - - Scientific and Clinical Advisor
David Hess - - Scientific and Clinical Advisor
Z. Kasey Rosado 50 2022 Interim CFO & Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ATHXQ Comments

Write your thoughts about Athersys Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email